98%
921
2 minutes
20
Aberrantly elevated steroid receptor coactivator-1 (SRC-1) expression and activity are strongly correlated with cancer progression and metastasis. Here we report, for the first time, the development of a proteolysis targeting chimera (PROTAC) that is composed of a selective SRC-1 binder linked to a specific ligand for UBR box, a unique class of E3 ligases recognizing N-degrons. We showed that the bifunctional molecule efficiently and selectively induced the degradation of SRC-1 in cells through the N-degron pathway. Importantly, given the ubiquitous expression of the UBR protein in most cells, PROTACs targeting the UBR box could degrade a protein of interest regardless of cell types. We also showed that the SRC-1 degrader significantly suppressed cancer cell invasion and migration in vitro and in vivo. Together, these results demonstrate that the SRC-1 degrader can be an invaluable chemical tool in the studies of SRC-1 functions. Moreover, our findings suggest PROTACs based on the N-degron pathway as a widely useful strategy to degrade disease-relevant proteins.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/anie.202005004 | DOI Listing |
J Biomol Struct Dyn
September 2025
Medical College, Hebei University of Engineering, Handan, China.
N-terminal glycine (Gly/N-degron), as a degradation signal, can be recognized by specific E3 ubiquitin ligases and plays a crucial role in protein degradation and cellular homeostasis. As a substrate receptor in the Cullin 2-RING E3 ligase complex, ZER1 mediates protein degradation the Gly/N-degron pathway by recognizing N-terminal glycine and other small residues. This study employed all-atom molecular dynamics (MD) simulations and binding free energy calculations to explore ZER1's recognition of the wild-type peptide GFLHVGQD (WT) and its N-terminal mutants (G1S, G1A, G1T, and G1C).
View Article and Find Full Text PDFCell Commun Signal
September 2025
Nucleic Acid Therapeutics Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang-eup, Cheongju-si, Chungcheongbuk-do, 28116, Republic of Korea.
Background: Arginyl-tRNA-protein transferase (ATE1) catalyzes N-terminal arginylation, a regulatory protein modification implicated in various cellular processes, including proliferation, apoptosis, and migration. Although ATE1 has context-dependent roles in cancer, its specific function in breast cancer remains unclear. This study investigates the oncogenic role of ATE1 across multiple breast cancer subtypes and its underlying molecular mechanisms.
View Article and Find Full Text PDFMethods Enzymol
August 2025
Department of Plant Physiology and Protein Metabolism Laboratory, University of Osnabruck, Osnabruck, Germany; CellNanOs-Center of Cellular Nanoanalytics, University of Osnabruck, Osnabruck, Germany; Faculty of Biology, University of Osnabruck, Osnabruck, Germany. Electronic address: nico.dissmeyer@
N-terminal arginylation is a posttranslational modification of proteins that may determine their fate with respect to their stability and half-life and timing of their physiological and molecular function. Arginylated N-termini are in some documented cases N-degrons leading to degradation through the proteasome or autophagic-lysosomal system (ALS) regulating cellular homeostasis and global physiological alterations. Proteins that are targets of arginyl-transferases (Ates) capable of ligating arginine (Arg) residues to N-terminal amino groups and internal side chains show therefore high importance for manipulation in therapeutic and research contexts.
View Article and Find Full Text PDFMethods Enzymol
August 2025
School of Chemistry, The University of Sydney, Sydney, NSW, Australia. Electronic address:
N-terminal cysteine oxidases (NCOs) regulate adaptive responses to hypoxia in animals and plants, functioning as enzymatic oxygen sensors which control the oxygen-dependant stability of proteins bearing an N-terminal cysteine residue (Nt-cys) through the N-degron pathway. However, the precise properties governing NCO activity and substrate selectivity remain poorly understood. This chapter details optimised protocols for investigating the binding interactions between 2-aminoethanethiol (cysteamine) dioxygenase (ADO), a mammalian NCO, and its Nt-cys substrates using surface plasmon resonance (SPR) spectroscopy.
View Article and Find Full Text PDFPharmaceutics
August 2025
Division of Magnetic Resonance, Korea Basic Science Institute (KBSI), Ochang, Cheongju 28119, Republic of Korea.
: Cervical cancer remains a major global health concern, with existing chemotherapy facing limited effectiveness owing to resistance. Polo-like kinase 1 (PLK1) overexpression in cervical cancer cells is a promising target for developing novel therapies to overcome chemoresistance and improve treatment efficacy. : In this study, we developed a novel PROTAC, NC1, targeting PLK1 PBD via the N-end rule pathway.
View Article and Find Full Text PDF